Biologic factors and response to radiotherapy in carcinoma of the cervix. Issue 3 (1st May 2001)

• Record Type: Journal Article
• Authors: Mukherjee, G.; Freeman, A.; Moore, R.; Devi, K. Uma; Morris, L. S.; Coleman, N.; Dilworth, S.; Prabhakaran, P. S.; Stanley, M. A.
• Is Part Of: International journal of gynecological cancer. Volume 11:Issue 3(2001)
• Page Start: 187
• Page End: 193
• Publication Date: 2001-05-01
• Subjects: bax protein -- bcl-2 protein -- p53 -- immunohistochemistry -- uterine cervix; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-00009577-200105000-00004
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Ionizing radiation has been used to treat cancers for a century. However, radioresistance remains a major problem in the clinic. Recent advances in the understanding of the molecular events that occur following ionizing radiation leading to DNA damage and repair, apoptosis, and cell cycle arrests suggest new ways in which the radiation response might be manipulated. Seventy-eight cases of carcinoma of the cervix of the same stage (II A and B) were analyzed retrospectively. All patients were treated with radiotherapy (RT) with a dose varying from 35 Gy to 50 Gy with 200 cGy per fraction. Subsequent to the completion of radiotherapy, all patients underwent surgery 4–6 weeks later. On histological examination of the surgical specimens, 51% of the cases (40) showed a complete response to therapy with no viable tumor cells. 49% of cases (38) had residual tumors ranging from a small focus to lesions extending through more than half the thickness of the cervical wall. p53 (mutant), bcl-2, p21 and bax proteins were studied on the paraffin sections of the biopsies (pretreatment) of those patients who failed to respond to RT and compared to similar studies on biopsies of patients who had a complete response to RT. In addition, the minichromosome maintenance (MCM) 2 proliferative marker was also done on all cases. Expression of all proteins was done using immunohistochemsitry. In the radioresistant cases, 15% (six cases) showed positivity for bcl-2 and p21, respectively, and 34% (13 cases) showed mutant p53. None of the radiosensitive tumors were positive for the above proteins. 75% of the radiosensitive tumors (30 cases) were positive for the bax antibody, whereas 81% of the radioresistant tumors (31 cases) were negative for bax. The MCM2 proliferative marker was positive in >80% of cells in 81.5% of radioresistant tumors (31 cases) as compared to <40% of cells that were positive in 70% of radiosensitive tumors (28 cases). The P -value for the biological markers was calculated using the chi-squared test, and was highly significant ( P <0.01) for all the parameters tested. However, there was no statistical significance by univariate analysis when the dose of radiation was analyzed with respect to the markers and the histological response. There was also no correlation between the radiation response and timing of surgery. The above data strongly suggest that bax, along with proliferative markers, could play a role in determining which tumors are likely to respond to radiation therapy. The presence of bcl-2, p21 and p53 could also be related to radioresistance of the tumors.